News
Among patients receiving semaglutide for obesity management, the risk for muscle loss may be higher in older adults and women ...
Case Western Reserve researchers found semaglutide users had significantly lower Alzheimer's-related dementia risk compared ...
If you’ve been taking Ozempic or Wegovy (both of which contain the active ingredient semaglutide), you might wonder, How long ...
Semaglutide, a popular anti-obesity drug, may come with a hidden cost: significant muscle loss, especially in women and older adults. A small study found that up to 40% of weight loss from semaglutide ...
Cheaper versions of medications to treat obesity, like Ozempic and Wegovy, could be on the market in Canada as soon as ...
Explore the implications of GLP-1 drugs in managing India's obesity crisis as experts warn of potential misuse and health ...
The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...
5h
Vietnam Investment Review on MSNAscletis Completes Dosing in US Obesity Drug Combo TrialAscletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that all the 28 participants have recently been dosed in the randomized, double-blind, placebo-controlled study (ASC47-103 study, NCT06972992) ...
There’s a perception that Ozempic, Wegovy and Zepbound are all you need to live a healthier life. But diet and exercise still ...
2h
Zacks.com on MSNNovo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.
The typical symptoms you have for stomach cancer, I had none of them, just the reflux,” Chloe Stirling shared of her shock ...
New research finds that men taking a GLP-1 for their obesity or type 2 diabetes often experience a rise in testosterone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results